Nipro Corporation (JP:8086)
:8086
Want to see JP:8086 full AI Analyst Report?
Top Page
Nipro
(8086)
Select Model
Select Model
Rating:62Neutral
Price Target:
¥1,733.00
▲(15.34% Upside)
Action:ReiteratedDate:10/30/25
Nipro's overall stock score reflects a mix of financial strengths and weaknesses, with solid revenue growth but challenges in profitability and leverage. Technical indicators suggest potential short-term weakness, while a high P/E ratio indicates overvaluation. The dividend yield offers some support but may not offset valuation concerns.
Positive Factors
Consistent Revenue Growth
A near-10% year-over-year revenue increase shows persistent demand across Nipro's medical device and pharma segments. Durable top-line growth supports scaling of manufacturing, long-term customer relationships, and provides a base for margin recovery and reinvestment over the next several quarters.
Negative Factors
High Financial Leverage
Elevated leverage reduces financial flexibility, raises interest and refinancing risk, and constrains strategic options like M&A or capex if margins weaken. In a capital-intensive medical supply business, high debt levels can pressurize liquidity and increase vulnerability to cyclical or operational shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
A near-10% year-over-year revenue increase shows persistent demand across Nipro's medical device and pharma segments. Durable top-line growth supports scaling of manufacturing, long-term customer relationships, and provides a base for margin recovery and reinvestment over the next several quarters.
Read all positive factors
Nipro (8086) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥243.10B
Dividend Yield2.03%
Average Volume (3M)504.50K
Price to Earnings (P/E)5.6
Beta (1Y)0.41
Revenue Growth4.10%
EPS Growth199.63%
CountryJP
Employees38,117
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)66.77
Shares Outstanding171,459,470
10 Day Avg. Volume391,050
30 Day Avg. Volume504,500
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)0.88
Price to Sales (P/S)0.34
P/FCF Ratio-27.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,500.00Price Target Upside-0.17% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)87.51
Revenue Forecast (FY)¥693.49B
Nipro Business Overview & Revenue Model
Company Description
Nipro Corporation (8086) is a global healthcare company headquartered in Japan, specializing in the development and manufacturing of medical devices, pharmaceuticals, and biotechnology. The company operates primarily in the areas of renal care, in...
How the Company Makes Money
NIPRO makes money primarily by selling medical devices and consumables and by supplying pharmaceutical-related packaging and delivery components, with revenues generated through ongoing demand from hospitals, clinics, dialysis providers, and pharm...
Nipro Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 649.95B | 644.59B | 586.78B | 545.20B | 494.79B | 455.56B |
| Gross Profit | 196.66B | 193.66B | 173.98B | 165.90B | 151.84B | 155.39B |
| EBITDA | 93.57B | 92.25B | 81.21B | 66.47B | 70.05B | 70.25B |
| Net Income | 10.89B | 5.11B | 11.11B | 4.58B | 13.46B | 14.21B |
Balance Sheet | ||||||
| Total Assets | 1.15T | 1.18T | 1.12T | 1.04T | 938.35B | 861.84B |
| Cash, Cash Equivalents and Short-Term Investments | 109.97B | 106.67B | 99.67B | 89.68B | 95.34B | 90.27B |
| Total Debt | 642.04B | 636.87B | 635.69B | 605.93B | 564.85B | 545.28B |
| Total Liabilities | 855.88B | 864.77B | 849.18B | 793.62B | 738.49B | 687.78B |
| Stockholders Equity | 238.94B | 252.45B | 232.66B | 206.32B | 185.24B | 161.03B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -8.15B | -21.33B | -74.70B | -11.74B | 14.35B |
| Operating Cash Flow | 0.00 | 68.46B | 72.94B | 10.39B | 68.21B | 66.09B |
| Investing Cash Flow | 0.00 | -71.88B | -87.08B | -71.74B | -78.43B | -45.07B |
| Financing Cash Flow | 0.00 | 5.38B | 22.14B | 43.08B | 10.30B | -22.06B |
Nipro Technical Analysis
Positive
1502.50
Price Trends
1541.13
Positive
1494.74
Positive
1464.17
Positive
Market Momentum
31.62
Positive
57.44
Neutral
32.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Positive. The current price of 1502.5 is below the 20-day moving average (MA) of 1594.47, below the 50-day MA of 1541.13, and above the 200-day MA of 1464.17, indicating a bullish trend. The MACD of 31.62 indicates Positive momentum. The RSI at 57.44 is Neutral, neither overbought nor oversold. The STOCH value of 32.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8086.
Nipro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥2.94T | 25.64 | 8.98% | 1.22% | 8.34% | 2.79% | |
71 Outperform | ¥830.33B | 16.38 | 9.38% | 1.88% | 0.22% | -22.56% | |
68 Neutral | ¥861.24B | 24.33 | 11.64% | 0.82% | 13.17% | -1.27% | |
62 Neutral | ¥243.10B | 5.59 | 4.38% | 2.03% | 4.10% | 199.63% | |
59 Neutral | ¥1.73T | 38.56 | 11.34% | 1.01% | 0.18% | 3.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:8086
Nipro
1,490.50
237.64
18.97%
JP:4543
Terumo
1,989.00
-804.85
-28.81%
JP:7747
Asahi Intecc Co
3,246.00
1,049.11
47.75%
JP:7733
Olympus
1,571.00
-351.55
-18.29%
JP:6869
Sysmex
1,331.50
-1,277.82
-48.97%
Nipro Corporate Events
Nipro to Shift Domestic Depreciation Method to Align With Overseas Operations
Mar 24, 2026
Nipro announced that it will change the depreciation method for property, plant, and equipment at the parent company and domestic consolidated subsidiaries from the declining-balance method to the straight-line method. The shift reflects that over...
Nipro Sets Record Date and Confirms Higher Year-End Dividend Forecast
Mar 11, 2026
Nipro Corporation’s board has set March 31, 2026 as the record date for shareholders eligible to receive the year-end dividend for the fiscal year ending March 2026, with notice to be provided electronically via its website. The company reaf...
Nipro Expands Governance With New Nomination and Compensation Committee
Feb 25, 2026
Nipro Corporation has decided to upgrade its existing Compensation Committee into a broader Nomination and Compensation Committee as a voluntary advisory body to the Board of Directors. The move, effective April 1, 2026, is designed to enhance fai...
Nipro books ¥5.2bn step-acquisition gain but keeps earnings forecast unchanged
Feb 9, 2026
Nipro Corporation has booked extraordinary income of 5.169 billion yen from a gain on step acquisition after increasing its equity stake in G2/Spryte Holdco, LLC on December 19, 2025, turning the entity into a consolidated subsidiary. The gain aro...
Nipro posts sharp profit rebound and keeps upbeat full-year outlook
Feb 9, 2026
Nipro reported consolidated results for the nine months ended Dec. 31, 2025, with net sales edging up 1.7% year-on-year to ¥487.3 billion, while operating profit jumped 20.5% to ¥26.7 billion and profit attributable to owners of parent s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.